Home › Companies › XERIS BIOPHARMA HOLDINGS INC. › 2023-2024

XERIS BIOPHARMA HOLDINGS INC. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and XERIS BIOPHARMA HOLDINGS INC.’s Form 8-K, filed 2024-06-05 (Item 5.07 on EDGAR). Page generated 04 October 2026.

10Reported items
145Asset managers
1,062Fund votes
2024-06-05Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore XERIS BIOPHARMA HOLDINGS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by XERIS BIOPHARMA HOLDINGS INC.

These tallies are XERIS BIOPHARMA HOLDINGS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2024-06-05 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

XERIS BIOPHARMA HOLDINGS INC. — official shareholder meeting results, meeting held 2024-06-05
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Paul R. Edick	58,524,066	--	--	6,505,672	36,161,541	Majority: yes
Elect Director: Ricki Fairley	58,511,772	--	--	6,520,445	36,159,062	Majority: yes
Elect Director: Marla S. Persky	47,442,889	--	--	17,566,155	36,182,235	Majority: yes
The Company's stockholders approved Proposal 2. The votes cast at the Annual Meeting were as follows*:	99,452,328	807,990	930,961	--	--	Majority: yes
The Company's stockholders approved Proposal 4. The votes cast at the Annual Meeting were as follows*:	57,804,619	6,665,428	562,170	--	36,159,062	Majority: yes
The Company's stockholders approved Proposal 5. The votes cast at the Annual Meeting were as follows*:	57,574,020	6,941,808	516,389	--	36,159,062	Majority: yes

Source: XERIS BIOPHARMA HOLDINGS INC., Form 8-K, filed with the SEC on 2024-06-05 — read the filing on EDGAR.

How asset managers voted at the XERIS BIOPHARMA HOLDINGS INC. 2023-2024 meeting

Each item below shows how the 145 asset managers that disclosed a XERIS BIOPHARMA HOLDINGS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of XERIS BIOPHARMA HOLDINGS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve, on a non-binding advisory basis, the compensation of our named executive officers.

OTHER

Meeting held 2024-06-05.

Combines 4 wordings of this item as funds reported it.

98% fund support · no official result

FOR 98%

The 139 asset managers below cast 98% of the shares they voted on this item FOR (40,559,149 for, 727,018 against).

FOR: 40,559,149 (98.1%)AGAINST: 727,018 (1.8%)ABSTAIN: 34,538 (0.1%)NOT VOTED: 20,000 (0.0%)ONE YEAR: 110 (0.0%)

Largest asset managers voting on “To approve, on a non-binding advisory basis, the compensation of our named executive officers.” at XERIS BIOPHARMA HOLDINGS INC., 2023-2024
Asset manager	For	Against	Vote
Vanguard	7,622,711	0	For
BlackRock	6,625,898	15,460	For
MPM BioImpact LLC	4,224,380	0	For
State Street	3,456,675	989	For
GEODE CAPITAL MANAGEMENT, LLC	2,710,536	0	For
Fidelity	2,523,618	0	For
Nuveen	1,199,882	0	For
TIAA	1,194,477	0	For
Northern Trust	1,132,462	0	For
Redmile Group, LLC	1,046,587	0	For
PNC BANK, NATIONAL ASSOCIATION	900,000	0	For
Charles Schwab	732,586	0	For
AQR	643,411	0	For
Knott David M Jr	600,000	0	For
MELLON INVESTMENTS Corp	0	597,478	Against
Invenomic Capital Management LP	580,580	0	For
NORTHERN LIGHTS FUND TRUST II	555,605	0	For
Lazard	430,489	0	For
Wellington	355,857	0	For
Equitable	324,647	0	For
QUANTITATIVE MASTER SERIES LLC	259,973	0	For
THOMPSON SIEGEL & WALMSLEY LLC	191,250	0	For
BROWN ADVISORY INC	190,255	0	For
Diversified Trust Co	175,739	0	For
Rubric Capital Management LP	175,101	0	For

Showing the 25 largest of 139 asset managers. See all 139 in the interactive database.

2. To indicate, on a non-binding advisory basis, the preferred frequency of future stockholder advisory votes on the compensation of our named executive officers.

OTHER

Meeting held 2024-06-05.

Combines 5 wordings of this item as funds reported it.

100% fund support · no official result

ONE YEAR 74%1 YEAR 26%

The 138 asset managers below cast 100% of the shares they voted on this item FOR (66,731 for, 0 against).

FOR: 66,731 (0.2%)ONE YEAR: 30,450,882 (73.7%)1 YEAR: 10,695,946 (25.9%)1-YEAR: 38,801 (0.1%)THREE YEARS: 30,031 (0.1%)2 YEARS: 25,000 (0.1%)NOT VOTED: 20,000 (0.0%)3 YEARS: 2,244 (0.0%)

Largest asset managers voting on “To indicate, on a non-binding advisory basis, the preferred frequency of future stockholder advisory votes on ” at XERIS BIOPHARMA HOLDINGS INC., 2023-2024
Asset manager	For	Against	Abstain	Withheld	Vote
Vanguard	0	0	0	0	One Year
BlackRock	0	0	0	0	One Year
MPM BioImpact LLC	0	0	0	0	1 Year
State Street	0	0	0	0	One Year
GEODE CAPITAL MANAGEMENT, LLC	0	0	0	0	One Year
Fidelity	0	0	0	0	One Year
Nuveen	0	0	0	0	One Year
TIAA	0	0	0	0	One Year
Northern Trust	0	0	0	0	1 Year
Redmile Group, LLC	0	0	0	0	1 Year
PNC BANK, NATIONAL ASSOCIATION	0	0	0	0	1 Year
Charles Schwab	0	0	0	0	1 Year
AQR	0	0	0	0	One Year
Knott David M Jr	0	0	0	0	One Year
MELLON INVESTMENTS Corp	0	0	0	0	One Year
Invenomic Capital Management LP	0	0	0	0	1 Year
NORTHERN LIGHTS FUND TRUST II	0	0	0	0	1 Year
Lazard	0	0	0	0	One Year
Wellington	0	0	0	0	1 Year
Equitable	0	0	0	0	One Year
QUANTITATIVE MASTER SERIES LLC	0	0	0	0	One Year
THOMPSON SIEGEL & WALMSLEY LLC	0	0	0	0	One Year
BROWN ADVISORY INC	0	0	0	0	One Year
Diversified Trust Co	0	0	0	0	1 Year
Rubric Capital Management LP	0	0	0	0	1 Year

Showing the 25 largest of 138 asset managers. See all 138 in the interactive database.

3. Election of Directors: Marla S. Persky

OTHERMajority of the votes cast: yes

Meeting held 2024-06-05.

Combines 2 wordings of this item as funds reported it.

73% Majority: yes · of votes cast

FOR 73%WITHHELD 27%

FOR: 47,442,889WITHHELD: 17,566,155

XERIS BIOPHARMA HOLDINGS INC.’s own tally for this item (“Elect Director: Marla S. Persky”): 47,442,889 for, 17,566,155 withheld, per its Form 8-K filed 2024-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 148,224,403 outstanding shares: 32% for, 12% withheld (44% of the company cast a for/withheld vote).

The 40 asset managers below cast 100% of the shares they voted on this item FOR (12,654,624 for, 0 against).

FOR 73%ABSTAIN 27%

FOR: 12,654,624 (72.5%)ABSTAIN: 4,793,779 (27.5%)

Largest asset managers voting on “Election of Directors: Marla S. Persky” at XERIS BIOPHARMA HOLDINGS INC., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	7,347,475	33	For
BlackRock	0	3,597,833	Abstain
Fidelity	2,514,522	0	For
TIAA	1,194,477	0	For
NORTHERN LIGHTS FUND TRUST II	555,605	0	For
State Street	452,788	606	For
Charles Schwab	366,293	0	For
Equitable	0	324,647	Abstain
QUANTITATIVE MASTER SERIES LLC	0	259,973	Abstain
Lincoln Financial	113,800	0	For
Principal Exchange-Traded Funds	0	73,974	Abstain
AIG/SunAmerica	0	65,577	Abstain
Northern Trust	59,679	0	For
ProShares	0	53,938	Abstain
John Hancock	0	52,066	Abstain
Pacific Life	0	44,656	Abstain
Voya	0	44,099	Abstain
Brighthouse	0	43,863	Abstain
MASTER INVESTMENT PORTFOLIO	0	35,697	Abstain
Nationwide	1,960	33,288	Abstain
SEI	29,100	0	For
Bridge Builder Trust	0	24,029	Abstain
Direxion Shares ETF Trust	0	21,932	Abstain
AQR	0	21,821	Abstain
DWS	0	20,745	Abstain

Showing the 25 largest of 40 asset managers. See all 40 in the interactive database.

4. Election of Directors: Paul R. Edick

OTHERMajority of the votes cast: yes

Meeting held 2024-06-05.

Combines 2 wordings of this item as funds reported it.

90% Majority: yes · of votes cast

FOR 90%10%

FOR: 58,524,066WITHHELD: 6,505,672

XERIS BIOPHARMA HOLDINGS INC.’s own tally for this item (“Elect Director: Paul R. Edick”): 58,524,066 for, 6,505,672 withheld, per its Form 8-K filed 2024-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 148,224,403 outstanding shares: 39% for, 4% withheld (44% of the company cast a for/withheld vote).

The 40 asset managers below cast 100% of the shares they voted on this item FOR (17,430,065 for, 0 against).

FOR 99.8%

FOR: 17,430,065 (99.9%)ABSTAIN: 18,338 (0.1%)

Largest asset managers voting on “Election of Directors: Paul R. Edick” at XERIS BIOPHARMA HOLDINGS INC., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	7,347,508	0	For
BlackRock	3,597,833	0	For
Fidelity	2,514,522	0	For
TIAA	1,194,477	0	For
NORTHERN LIGHTS FUND TRUST II	555,605	0	For
State Street	453,362	32	For
Charles Schwab	366,293	0	For
Equitable	324,647	0	For
QUANTITATIVE MASTER SERIES LLC	259,973	0	For
Lincoln Financial	113,800	0	For
Principal Exchange-Traded Funds	73,974	0	For
AIG/SunAmerica	65,577	0	For
Northern Trust	59,679	0	For
ProShares	53,938	0	For
John Hancock	52,066	0	For
Pacific Life	44,656	0	For
Voya	44,099	0	For
Brighthouse	43,863	0	For
MASTER INVESTMENT PORTFOLIO	35,697	0	For
Nationwide	35,248	0	For
SEI	29,100	0	For
Bridge Builder Trust	24,029	0	For
Direxion Shares ETF Trust	21,932	0	For
AQR	21,821	0	For
DWS	20,745	0	For

Showing the 25 largest of 40 asset managers. See all 40 in the interactive database.

5. Election of Directors: Ricki Fairley

OTHERMajority of the votes cast: yes

Meeting held 2024-06-05.

Combines 2 wordings of this item as funds reported it.

90% Majority: yes · of votes cast

FOR 90%10%

FOR: 58,511,772WITHHELD: 6,520,445

XERIS BIOPHARMA HOLDINGS INC.’s own tally for this item (“Elect Director: Ricki Fairley”): 58,511,772 for, 6,520,445 withheld, per its Form 8-K filed 2024-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 148,224,403 outstanding shares: 39% for, 4% withheld (44% of the company cast a for/withheld vote).

The 40 asset managers below cast 100% of the shares they voted on this item FOR (17,330,827 for, 0 against).

FOR 99.3%

FOR: 17,330,827 (99.3%)ABSTAIN: 117,576 (0.7%)

Largest asset managers voting on “Election of Directors: Ricki Fairley” at XERIS BIOPHARMA HOLDINGS INC., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	7,347,508	0	For
BlackRock	3,597,833	0	For
Fidelity	2,514,522	0	For
TIAA	1,194,477	0	For
NORTHERN LIGHTS FUND TRUST II	555,605	0	For
State Street	453,394	0	For
Charles Schwab	366,293	0	For
Equitable	225,377	99,270	For
QUANTITATIVE MASTER SERIES LLC	259,973	0	For
Lincoln Financial	113,800	0	For
Principal Exchange-Traded Funds	73,974	0	For
AIG/SunAmerica	65,577	0	For
Northern Trust	59,679	0	For
ProShares	53,938	0	For
John Hancock	52,066	0	For
Pacific Life	44,656	0	For
Voya	44,099	0	For
Brighthouse	43,863	0	For
MASTER INVESTMENT PORTFOLIO	35,697	0	For
Nationwide	35,248	0	For
SEI	29,100	0	For
Bridge Builder Trust	24,029	0	For
Direxion Shares ETF Trust	21,932	0	For
AQR	21,821	0	For
DWS	20,745	0	For

Showing the 25 largest of 40 asset managers. See all 40 in the interactive database.

6. To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2024.

OTHER

Meeting held 2024-06-05.

Combines 2 wordings of this item as funds reported it.

100% fund support · no official result

FOR 100%

The 40 asset managers below cast 100% of the shares they voted on this item FOR (17,448,403 for, 0 against).

FOR: 17,448,403 (100.0%)

Largest asset managers voting on “To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Com” at XERIS BIOPHARMA HOLDINGS INC., 2023-2024
Asset manager	For	Vote
Vanguard	7,347,508	For
BlackRock	3,597,833	For
Fidelity	2,514,522	For
TIAA	1,194,477	For
NORTHERN LIGHTS FUND TRUST II	555,605	For
State Street	453,394	For
Charles Schwab	366,293	For
Equitable	324,647	For
QUANTITATIVE MASTER SERIES LLC	259,973	For
Lincoln Financial	113,800	For
Principal Exchange-Traded Funds	73,974	For
AIG/SunAmerica	65,577	For
Northern Trust	59,679	For
ProShares	53,938	For
John Hancock	52,066	For
Pacific Life	44,656	For
Voya	44,099	For
Brighthouse	43,863	For
MASTER INVESTMENT PORTFOLIO	35,697	For
Nationwide	35,248	For
SEI	29,100	For
Bridge Builder Trust	24,029	For
Direxion Shares ETF Trust	21,932	For
AQR	21,821	For
DWS	20,745	For

Showing the 25 largest of 40 asset managers. See all 40 in the interactive database.

7. To approve an amendment to the Xeris Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan, to (i) remove the "evergreen" provision which provides for annual increases in the aggregate number of shares available for issuance thereunder and (ii) increase the aggregate number of shares available for issuance thereunder by 6,636,632 additional shares.

OTHER

Meeting held 2024-06-05.

100% fund support · no official result

FOR 100%

The 36 asset managers below cast 100% of the shares they voted on this item FOR (17,370,064 for, 0 against).

FOR: 17,370,064 (100.0%)

Largest asset managers voting on “To approve an amendment to the Xeris Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan, to (i) remove th” at XERIS BIOPHARMA HOLDINGS INC., 2023-2024
Asset manager	For	Vote
Vanguard	7,347,508	For
BlackRock	3,597,833	For
Fidelity	2,514,522	For
TIAA	1,194,477	For
NORTHERN LIGHTS FUND TRUST II	555,605	For
State Street	453,394	For
Charles Schwab	366,293	For
Equitable	324,647	For
QUANTITATIVE MASTER SERIES LLC	259,973	For
Lincoln Financial	113,800	For
Principal Exchange-Traded Funds	73,974	For
AIG/SunAmerica	65,577	For
Northern Trust	59,679	For
ProShares	53,938	For
Pacific Life	44,656	For
Voya	44,099	For
Brighthouse	43,863	For
MASTER INVESTMENT PORTFOLIO	35,697	For
Nationwide	35,248	For
SEI	29,100	For
Direxion Shares ETF Trust	21,932	For
AQR	21,821	For
DWS	20,745	For
Principal	17,868	For
Victory Capital	17,355	For

Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.

8. To approve an amendment to the Xeris Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan, to (i) remove the "evergreen" provision which provides for annual Increase in the aggregate number of shares available for issuance thereunder and (ii) increase the aggregate number of shares available for issuance thereunder by 6,636,632 additional shares

CAPITAL STRUCTURE

Meeting held 2024-06-05.

100% fund support · no official result

FOR 100%

The 4 asset managers below cast 100% of the shares they voted on this item FOR (78,339 for, 0 against).

FOR: 78,339 (100.0%)

Largest asset managers voting on “To approve an amendment to the Xeris Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan, to (i) remove th” at XERIS BIOPHARMA HOLDINGS INC., 2023-2024
Asset manager	For	Vote
John Hancock	52,066	For
Bridge Builder Trust	24,029	For
Jackson National	1,389	For
Allianz	855	For

9. To approve, on a non-binding advisory basis, the compensation of our named executive officers.

SECTION 14A SAY-ON-PAY VOTES

Meeting held 2025-06-04 (outside the 2023-2024 season's 1 July to 30 June window; reported in this season's filings).

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (1,500 for, 0 against).

FOR: 1,500 (100.0%)

Largest asset managers voting on “To approve, on a non-binding advisory basis, the compensation of our named executive officers.” at XERIS BIOPHARMA HOLDINGS INC., 2023-2024
Asset manager	For	Against	Abstain	Withheld	Vote
MBA Advisors LLC	1,000	0	0	0	For
Foster Victor Wealth Advisors, LLC	500	0	0	0	For

10. 14A Executive Compensation

SECTION 14A SAY-ON-PAY VOTES

Meeting held 2024-06-05.

Combines 2 wordings of this item as funds reported it.

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (226 for, 0 against).

FOR: 226 (100.0%)

Largest asset managers voting on “14A Executive Compensation” at XERIS BIOPHARMA HOLDINGS INC., 2023-2024
Asset manager	For	Against	Abstain	Withheld	Vote
Granite Investment Partners, LLC	226	0	0	0	For
HARBOUR INVESTMENT MANAGEMENT LLC	0	0	0	0	--

Largest XERIS BIOPHARMA HOLDINGS INC. shareholders voting in 2023-2024

Ranked by the number of XERIS BIOPHARMA HOLDINGS INC. shares each manager voted on the most widely held ballot item of the 2023-2024 meeting, shown as a share of the 148,224,403 shares outstanding at the time of that meeting.

Top XERIS BIOPHARMA HOLDINGS INC. shareholders by shares voted, 2023-2024
#	Asset manager	% of shares outstanding
1	Vanguard	5.14%
2	BlackRock	4.48%
3	MPM BioImpact LLC	2.85%
4	State Street	2.33%
5	GEODE CAPITAL MANAGEMENT, LLC	1.83%
6	Fidelity	1.70%
7	Nuveen	0.81%
8	TIAA	0.81%
9	Northern Trust	0.76%
10	Redmile Group, LLC	0.71%

Reported XERIS BIOPHARMA HOLDINGS INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

XERIS BIOPHARMA HOLDINGS INC. beneficial owners on record for the 2023-2024 proxy season
Holder	% outstanding	Disclosure
BlackRock	8.05%	13F
Vanguard Group	6.63%	13F
Morgan Stanley	2.17%	13F
State Street	2.17%	13F
Geode Capital	2.05%	13F
Goldman Sachs	1.21%	13F
Millennium Management	1.14%	13F
Nuveen	1.07%	13F
Northern Trust	0.78%	13F
AQR Capital	0.77%	13F

Percentages above are of 148,224,403 shares outstanding, as reported by XERIS BIOPHARMA HOLDINGS INC. on its Form 10-Q dated 2024-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from XERIS BIOPHARMA HOLDINGS INC.’s 10-Q dated 2024-03-31. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.

At XERIS BIOPHARMA HOLDINGS INC.'s shareholder meeting held 2024-06-05, in the 2023-2024 proxy season, 145 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,062 separate fund positions. Their filings are grouped here into 10 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. XERIS BIOPHARMA HOLDINGS INC.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — To approve, on a non-binding advisory basis, the compensation of our named executive officers. — the reporting funds cast 98% of the shares they voted in favour (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). That is the aggregate of those managers' own N-PX disclosures, not the company's certified result, and the funds are a subset of all shareholders.

XERIS BIOPHARMA HOLDINGS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.